Express Scripts (ESRX) Mylan Selloff Is Overdone - Jefferies
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies analyst, Brian Tanquilut believes the pressure on Express Scripts (NASDAQ: ESRX) due to concerns about potential pricing scrutiny for players in the drug supply chain, including the PBMs and retail pharmacies is overdone. The analyst believes that the PBMs enable health plan benefit sponsors to optimize costs through clinical programs, scale purchasing, and new tools/offerings such as inflation protection and cost trend guarantees, which he believes plan sponsors generally recognize.
No change to the Buy rating or price target of $88.
Shares of Express Scripts closed at $71.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Boston Beer Co. (SAM) to $140 Following Weak 3Q
- Jefferies Raises Price Target on ICON plc (ICLR) to $87.50; Reiterates Hold
- RBC Capital Raises Price Target on Benchmark Electronics (BHE) Following In-Line 3Q
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!